RSV Vaccine Segmentation for Immune Balance
Solution Overview
Problem
Current RSV vaccines induce vaccine-induced disease (VID) due to excessive T cell responses, leading to lung pathology, and none have successfully balanced neutralizing antibody induction with suppression of inflammatory CD4+ T cells.
Innovation Solution
A vaccine comprising an RSV antigenic peptide and DNA encoding the peptide, specifically stimulating iTreg cells (CD4+, CD25-, FoxP3+, IL-10+) to induce neutralizing antibodies while suppressing inflammatory T cell responses, using a nucleic acid and antigen mass ratio between 5:1 and 1:5, and administered via electroporation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RSV vaccines are designed to induce neutralizing antibodies, then protective immunity is improved, but excessive T cell responses are triggered causing vaccine-induced disease
Solution Approach 1:
The vaccine composition is segmented into two distinct components: a protein component containing RSV antigenic peptides and a nucleic acid component encoding said peptides. This segmentation allows each component to perform its specific function - the protein induces neutralizing antibodies while the nucleic acid stimulates regulatory T cells that suppress excessive inflammatory responses, thereby resolving the contradiction between protective immunity and vaccine-induced disease
Solution Approach 2:
The nucleic acid component acts as an intermediary that modulates the immune response. It encodes RSV antigenic peptides that are processed and presented to stimulate iTreg cells, which then serve as mediators to suppress excessive inflammatory CD4+ T cell responses while allowing the protein component to induce protective neutralizing antibodies
2Quantity of substance
If conventional RSV vaccines are administered, then immune response is stimulated, but lung pathology and airway hyper-responsiveness occur
Solution Approach 1:
The vaccine employs specific parameter changes in the form of optimized mass ratios between the nucleic acid and protein components (ranging from 5:1 to 1:5). This parameter optimization ensures that the nucleic acid component sufficiently stimulates regulatory T cells to suppress inflammatory responses, while the protein component effectively induces neutralizing antibodies, thereby achieving protective immunity without lung pathology
Solution Approach 2:
The vaccine is formulated as a composite composition containing both protein and nucleic acid components with specific mass ratios. This composite structure allows synergistic interaction where the protein induces protective antibodies and the nucleic acid induces regulatory T cells that prevent excessive inflammation and lung pathology, resolving the contradiction between immune response quantity and harmful effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vaccine effectively prevents RSV infection by inducing neutralizing antibodies and suppressing inflammatory T cell responses, reducing pulmonary abnormalities and airway hyper-responsiveness, thereby minimizing VID.
Implementation Method 1
a nucleic acid encoding the RSV antigenic peptide, wherein the nucleic acid is DNA and the DNA encodes for the RSV antigenic peptide
Implementation Method 2
administered via electroporation
Data Source
Figure 1
Figure 2A~2B
Figure 3
AI summary
Treating and preventing symptoms of respiratory syncytial virus (RSV) infection using a combination vaccine containing an RSV antigen and a DNA encoding the RSV antigen is provided.